ArticleJournal of the American Heart Association2025
Risk of Coronary Artery Disease Associated With Transitions in Metabolic Health in a Clinical Cohort of 69 272.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Phenome- and laboratory-wide meta-analyses of sickle cell trait reveal multi-system disease associations.American journal of human genetics · 2026Pooled it
- Metabolic health and cardiovascular outcomes in treated hypertension: a secondary analysis of SPRINT.Clinical hypertension · 2026Article
- A protocol for the impact of Tongmai Jiangtang capsules on the risk of cardiovascular and cerebrovascular events in metabolic syndrome.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThe effect of recent onset metabolic dysfunction on coronary artery disease (CAD) risk is poorly understood. We developed a large data set linking metabolic phenotypes and clinical outcomes to quantify CAD risks associated with adverse metabolic transition.
methodsClinical parameters, measures of metabolic dysfunction components (diabetes, hypertension, elevated triglycerides, and low high-density lipoprotein) and incident CAD were curated in a clinical cohort from a single quaternary medical center. Associations between body weight, metabolic abnormalities, and changes in metabolic health status were assessed for prevalent and incident CAD.
resultsIncreasing body mass index category, presence of metabolic dysfunction (>2 components), and number of metabolic abnormalities were associated with prevalent CAD among 844 841 individuals. In time-to-event analyses (N=69 272), ~38% of subjects initially free of any metabolic dysfunction abnormality developed ≥1 abnormality over a 3-year run-in period. All metabolic abnormalities, whether new-onset or preexisting, significantly increased 10-year CAD event probability, and there was a progressive increase in 10-year CAD risk with increasing burden of metabolic abnormalities. In models adjusting for metabolic dysfunction, 10-year CAD risk increased for individuals with body mass index >25 kg/m
conclusionsIn a large clinical cohort, the transition to metabolic dysfunction is common, occurs rapidly, and significantly increases incident CAD risk. The effect of body weight and weight loss on CAD risk is nonlinear. Interventions to prevent progression to metabolic dysfunction are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.